2 weeks Ago By ABMN Staff
Russell Investments Group Ltd. lifted its position in shares of Kura Oncology, Inc. ( NASDAQ:KURA – Free Report ) by 18.
2% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 298,662 shares of the company’s stock after buying an additional 45,892 shares during the quarter. Russell Investments Group Ltd.
owned about 0.38% of Kura Oncology worth $2,601,000 as of its most recent SEC filing. Other hedge funds and other institutional investors also recently modified their holdings of the company.
Barclays PLC increased its position in Kura Oncology by 104.5% during the third quarter. Barclays PLC now owns 165,484 shares of the company’s stock worth $3,234,000 after acquiring an additional 84,563 shares during the period.
SG Americas Securities LLC acquired a new position in shares of Kura Oncology during the 4th quarter worth approximately $436,000. Moody Aldrich Partners LLC increased its holdings in shares of Kura Oncology by 42.3% during the fourth quarter.
Moody Aldrich Partners LLC now owns 143,587 shares of the company’s stock worth $1,251,000 after purchasing an additional 42,712 shares during the period. Harbor Capital Advisors Inc. raised its position in shares of Kura Oncology by 4.
4% in the fourth quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company’s stock valued at $430,000 after buying an additional 2,076 shares in the last quarter.
Finally, Jennison Associates LLC bought a new stake in shares of Kura Oncology in the fourth quarter valued at approximately $623,000. Analyst Upgrades and Downgrades Several equities analysts have weighed in on KURA shares. UBS Group cut their target price on Kura Oncology from $27.
00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, March 6th. Scotiabank reduced their price objective on shares of Kura Oncology from $18.
00 to $10.00 and set a “sector perform” rating on the stock in a research note on Wednesday, January 8th. BTIG Research cut shares of Kura Oncology from a “buy” rating to a “neutral” rating in a research report on Thursday, February 6th.
Wedbush reiterated an “outperform” rating and set a $36.00 price target on shares of Kura Oncology in a research report on Tuesday, April 8th. Finally, StockNews.
com upgraded shares of Kura Oncology from a “hold” rating to a “buy” rating in a research report on Friday, April 4th. Three research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.
com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $25.50. Kura Oncology Stock Up 2.
6 % Shares of NASDAQ KURA opened at $5.90 on Friday. The company has a 50 day simple moving average of $7.
18 and a 200 day simple moving average of $10.64. The company has a debt-to-equity ratio of 0.
02, a current ratio of 11.47 and a quick ratio of 11.47.
Kura Oncology, Inc. has a 1 year low of $5.41 and a 1 year high of $23.
48. The firm has a market cap of $476.59 million, a PE ratio of -2.
50 and a beta of 0.83. Kura Oncology ( NASDAQ:KURA – Get Free Report ) last issued its quarterly earnings results on Wednesday, February 26th.
The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.
43. The business had revenue of $53.88 million for the quarter, compared to analyst estimates of $57.
96 million. On average, research analysts forecast that Kura Oncology, Inc. will post -2.
44 EPS for the current year. Insider Buying and Selling at Kura Oncology In related news, insider Mollie Leoni sold 4,963 shares of the business’s stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.
87, for a total value of $39,058.81. Following the transaction, the insider now owns 88,253 shares in the company, valued at $694,551.
11. The trade was a 5.32 % decrease in their ownership of the stock.
The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink . Also, SVP Thomas James Doyle sold 4,949 shares of the stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.
87, for a total value of $38,948.63. Following the sale, the senior vice president now owns 88,193 shares of the company’s stock, valued at approximately $694,078.
91. The trade was a 5.31 % decrease in their ownership of the stock.
The disclosure for this sale can be found here . In the last quarter, insiders have sold 11,729 shares of company stock worth $92,307. Insiders own 5.
50% of the company’s stock. Kura Oncology Profile ( Free Report ) Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer.
Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. Further Reading Want to see what other hedge funds are holding KURA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kura Oncology, Inc.
( NASDAQ:KURA – Free Report ). Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter .
.
